Omnitus, 50 mg 10 pcs

A cough suppressant, has expectorant, moderate bronchodilator and anti-inflammatory effect.

Butamyrate citrate is neither chemically nor pharmacologically related to opium alkaloids and has a direct effect on the cough center, improves spirometry and blood oxygenation.

Pharmacokinetics

Absorption is high.

After oral administration of a syrup containing 150 mg of butamirate citrate, the maximum plasma concentration of the main metabolite (2-phenyl butyric acid) is observed after 1.5 h and is 6.4 µg/ml; when taking the modified-release tablet (50 mg), it is 9 h and 1.4 µg/ml, respectively.

The elimination half-life for syrup is 6 h, for tablets 13 h. There is no cumulative effect. Butamyrate citrate is rapidly hydrolyzed in plasma to 2-phenyl butyric acid and diethylaminoethoxyethanol.

Both of these metabolites, which also have antitussive effects, are largely bound to plasma proteins, which explains their prolonged presence in plasma.

The main metabolite 2-phenyl butyric acid is further oxidized to 14C-p-hydroxy-2-phenyl butyric acid.

All three metabolites are excreted by the kidneys, with the acidic metabolites mostly bound to glucuronic acid.

Indications

Suppression of cough in preoperative and postoperative period, during surgery, bronchoscopy. Dry cough of any etiology (colds, flu, whooping cough and other conditions).

Active ingredient

Composition

How to take, the dosage

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Symptoms: nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure.

Treatment: orally – activated charcoal, saline laxatives, if necessary – symptomatic therapy.

Pregnancy use

Contraindicated during lactation, pregnancy, children and adolescents under 18 years of age.

Similarities